Last reviewed · How we verify

NCT07149740

Data Gathering for A10900

Recruiting now Last updated 13 February 2026
What this trial tests

trial testing OCT in Retinal Disease in 180 participants. Currently enrolling.

Timeline
26 June 2025
Primary endpoint
1 May 2026
1 May 2026

Quick facts

Lead sponsorOptos, PLC
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment180
Start date26 June 2025
Primary completion1 May 2026
Estimated completion1 May 2026
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Optos, PLC

Who can join

22 and older, any sex, with Retinal Disease or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of OCT

Trials testing the same drug.

Other recruiting trials for Retinal Disease

Currently open trials in the same condition.

Other Optos, PLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07149740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing